Highly motivated to develop and expand cancer therapies, cancer research pioneer Clay Siegall has worked tirelessly to achieve advancements in inventive therapies for cancer patients.
Since co-founding Seattle Genetics in 1998, Siegall has almost twenty years in guiding the company to new scientific achievements. He is the current president, chief executive officer and chairman of the board of Seattle Genetics.
Siegall’s intense enthusiasm and passion have made it easier for him to lead the company to undertake new levels of research development.
Under his direction the company has built a diverse channel of antibody-based cancer therapies through its proprietary, industry leading technology.
Specifically, Seattle Genetics has built up its antibody-drug conjugate (ADC) technology that brings into play antibodies or other biologics produced by a single cell that transports highly active pharmaceutical ingredients to targeted cells.
ADCs, including the company’s first ADC product ADCETRIS, is now available in more than 60 countries.
Seattle Genetics has entered into many collaborations for its ADC technology including with companies such as GlaxoSmithKline, Pfizer, Genentech (Roche) and others.
Aside from his success in the new cancer therapy line of work, Siegall has proven his impact through his fundraising expertise.
For example, he has led Seattle Genetics’ capital raising interests through private and public financings by securing more than $1.2 billion. And the company’s stock price has nearly tripled over a five year period.
Siegall, who holds 15 patents, has also published more than 70 scientific pieces of writing. He has been recognized for his scientific contributions with many awards including The University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences as well as the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year.
What’s more he is a board member of Mirna Therapeutics, Ultragenyx Pharmaceutical, Alder BioPharmaceuticals and Washington Roundtable.
Siegall graduated with a B.S. degree from the University of Maryland and went on to receive a Ph.D. from George Washington University. He started on his career as a senior research investigator at the Bristol-Myers Squibb Pharmaceutical Research Institute.